Despite preventive treatment, HAE patients require on-demand care
Even with long-term preventive treatment, many people with hereditary angioedema still sometimes have swelling attacks that require on-demand treatment, a review study finds.
News
Despite multiple swelling attacks, HAE diagnosis delayed for children
Children with hereditary angioedema (HAE) may have dozens of swelling attacks until they receive a correct diagnosis of the disease, according to a study in a hospital in Turkey, where the median delay was three years. “Awareness of the symptoms of HAE is necessary and correct diagnosis is…
Researchers define clinically meaningful score change in angioedema test
A 3-point score increase is the minimum change on the widely used Angioedema Control Test (AECT) to reflect meaningful improvement in disease control for people with recurrent angioedema, a study showed. The AECT was developed to help patients keep score of disease control over a recall period, but…
EMA grants PRIME designation to NTLA-2002 gene-editing therapy
The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to Intellia Therapeutics’ NTLA-2002, an experimental gene-editing therapy to prevent swelling attacks in people with hereditary angioedema (HAE). A PRIME designation supports the development of experimental therapies that address unmet medical needs. Eligibility for this status is…
Patient feedback helps in design of Phase 3 trial of oral sebetralstat
The design of an ongoing Phase 3 clinical trial testing sebetralstat as an on-demand oral treatment for swelling attacks in hereditary angioedema (HAE) was based on feedback from patients and data from a previous Phase 2 trial. The approach was described in the study “Evaluation…
Acquired angioedema can be treated with off-label use of HAE therapies
On-demand and preventive treatment with either icatibant injection or C1 inhibitor (C1-INH) concentrates — which are approved for hereditary angioedema (HAE) — also can help people with acquired angioedema keep swelling under control, according to a small study in Germany. People severely affected with acquired angioedema and no “underlying condition…
Takhzyro prevents HAE attacks, boosts life quality in children: Study
Up to one year of treatment with Takhzyro (lanadelumab) significantly reduced rates of swelling attacks and improved quality of life for children with hereditary angioedema (HAE) ages 2 through 11, according to results from the Phase 3 SPRING clinical trial. Results from the trial helped support the U.S.
More needs to be done to educate emergency workers on HAE: Study
New treatments for hereditary angioedema (HAE) have been life-changing for people in the U.K., but more and better efforts are needed to educate emergency workers on providing care, according to a new study. The survey study found that HAE patients in Great Britain still frequently have upsetting experiences when…
EU panel recommends Takhzyro for children as young as 2
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the approval of Takhzyro (lanadelumab) for the routine prevention of hereditary angioedema (HAE) attacks in children starting at age 2. Based on a positive opinion from the CHMP, the European…
ACE inhibitor ID’d as likely cause of angioedema after surgery: Case
A 46-year-old man developed delayed angioedema following surgery — with his tongue swelling significantly four hours later — that likely was triggered by the use of an ACE or angiotensin-converting enzyme inhibitor to treat his high blood pressure, according to a new case report. Due to rapid evaluation by…
Recent Posts
- How I’m enduring my dual battles of body and mind
- Treatments helping to control HAE boost life quality: Study in India
- Sometimes fixing a problem is easier than we expect
- Phase 3 trial of sebetralstat for young HAE patients is fully enrolled
- Are you tired, fatigued, or exhausted? What’s the difference?